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Glaucoma refers to a group of optic neuropathies charac-
terized by the selective and progressive degeneration of retinal 
ganglion cells (RGCs) with associated visual field defects. 
The most common form of glaucoma is chronic open angle 
glaucoma (OAG) in which the iridocorneal angle remains 
open, and intraocular pressure (IOP) elevation is caused by 
stiffening of the trabecular meshwork (TM) and associated 
ciliary muscles (CMs) due to the build-up of plaques and 
fibrosis in and around the drainage canals, reducing aqueous 
humor (AqH) outflow. Elevated IOP is the main modifiable 
risk factor for the development of glaucoma leading to RGC 
death and loss of vision [1].
Most AqH drains through the TM in the iridocorneal 
angle, into Schlemm’s canal (SC) and then the episcleral 
veins. Smooth muscle contractions between the TM and 
CMs mostly control AqH outflow through being able to 
alter the stiffness and tone of the TM [2]. The extracellular 
matrix (ECM) also determines outflow resistance through 
the juxtacanalicular region of the TM [3]. Pathologically high 
resistance to AqH outflow maybe due to the transformation 
of TM cells to myofibroblast-like cells [4] (leading to a loss 
of TM cell numbers) and from the development of sheath-
derived plaques and increased ECM deposition within the 
TM, which all contribute to decreasing AqH outflow [5]. The 
sheath-derived plaques may be the more important cause of 
high outflow resistance that correlates with the severity of 
optic nerve (ON) damage [6]. In current clinical practice, IOP 
is reduced by (1) impeding AqH production using β-blockers 
[7], α-agonists, and carbonic anhydrase inhibitors [8] and 
increasing AqH outflow by either prostaglandin analogs or 
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TGF-β-induced IOP elevations are mediated by RhoA in the early 
but not the late fibrotic phase of open angle glaucoma
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Purpose: Elevations in intraocular pressure (IOP) are associated with the development of glaucoma and loss of sight. 
High transforming growth factor-β (TGF-β) 1 levels in the eye’s anterior chamber can lead to dysfunctional contrac-
tions through RhoA signaling in trabecular meshwork (TM) cells and IOP spikes. Sustained high TGF-β levels leads to 
TM fibrosis and sustained increases in IOP. We investigated whether inhibiting RhoA, using a siRNA-mediated RhoA 
(siRhoA), controls IOP by altering TM expression of fibrosis and contractility-related proteins in a rodent model of 
glaucoma.
Methods: TGF-β was injected intracamerally twice a week into adult Sprague Dawley rats, and IOP was recorded with 
tonometry. Animals were euthanized on day 7 and 35 with TM expression of fibrosis and contractility-related proteins, as 
well as survival of retinal ganglion cells (RGCs) assessed with immunohistochemistry. siRNA against RhoA or enhanced 
green fluorescent protein (EGFP) was also injected intracamerally into select animals. Successful RhoA knockdown was 
determined with quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry, 
and the effects of the knockdown on the parameters above analyzed.
Results: TGF-β caused increased TM contractile proteins and IOP spikes by day 7, sustained increases in IOP from day 
15, and TM fibrosis at day 35. siRhoA abolished the transient 7 day IOP rise but not the later sustained IOP increase (due 
to fibrosis). At 35 days, TGF-β-related RGC loss was not prevented with siRhoA treatment.
Conclusions: We conclude that RhoA signaling mediates the early IOP rise induced by TM cellular changes associated 
with contractility but not the sustained IOP elevation caused by TM fibrosis. Thus, RhoA therapies offer a clinically 
relevant opportunity for IOP management, likely through the modulation of TM contractility, but appear to be ineffective 
in the amelioration of fibrosis.
Correspondence to: Lisa Hill, Institute of Clinical Sciences, 
University of Birmingham, Birmingham, B15 2TT, United 
Kingdom; Phone: +44(0) 0121 414 6620; email: L.J.Hill@bham.
ac.uk
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α-agonist treatment and surgery to reduce the resistance to 
AqH drainage, for example, by trabeculectomy [9]. Current 
medical treatments slow but often do not arrest disease 
progression, and surgery carries considerable risks. There-
fore, there is an unmet clinical need for new therapies that 
target the disease etiology.
Transforming growth factor-β (TGF-β) 1 [10] and TGF-β2 
isoforms induce TM and CM contraction and ECM deposition 
in patients with OAG, with levels significantly elevated in the 
AqH of patients with OAG [9] compared to control patients 
with cataract [11] or primary closed angle glaucoma [12,13]. 
In patients with secondary OAG, higher levels of the TGF-β1 
isoform occur as seen most commonly in pseudoexfoliation 
glaucoma, while in those with primary OAG, the TGF-β2 
isoform is raised. TGF-β1 and TGF-β2 induce ECM depo-
sition in cultured Tenon’s capsule fibroblasts [14] and TM 
cells derived from patients with glaucoma [15] by signaling 
through the Smad pathway [16]. That expression of fibro-
nectin and collagen (associated with reduced AqH outflow in 
vivo) is increased by these growth factors in a concentration-
dependent manner as shown in human and porcine-derived 
TM cells [14,17]. TGF-β1 also induces ECM remodelling in 
the TM by altering the metalloproteinase (MMP) to tissue 
inhibitors of the MMP (TIMP) ratio to favor deposition of 
ECM [18,19].
Activation of the RhoA/Rho-kinase (ROCK) signaling 
pathway within TM cells induces actin filament contrac-
tion and polymerization through phosphorylation of LIM 
kinase-2 and myosin light chain (MLC) [20], causing the 
TM to contract (i.e., become more stiff) altering resistance 
to outflow in the TM. Inhibiting contractile machinery (i.e., 
reducing the stiffness) in TM cells has been shown to effec-
tively lower IOP in human TM cells [21,22] and in rats [21] 
through its ability to enhance TM permeability by increasing 
intracellular spaces for AqH to flow more easily [23]. RhoA 
is a small G-protein activated by phosphorylation of guano-
sine diphosphate (GDP) into guanosine triphosphate (GTP) 
[24] after receptor binding by the ECM proteins laminin 
[25], collagen [26], and fibronectin [27] and by endothelin-1 
[28], thrombin [29], and TGF-β [24,30]. When TGF-β binds 
receptor 1 (ALK5) on TM cells there is activation of a down-
stream signal transduction cascade so that RhoA-GTP and 
ROCK are activated. This is associated with raised expres-
sion of alpha smooth muscle action (α-SMA) and MLC-p and 
correlated with increased TM contractility, reduced AqH 
drainage, and a rapid IOP rise [31]. In rabbits, intracameral 
(IC) injection of the ROCK inhibitor Y-27632 reduces IOP, 
probably by reducing the RhoA signaling cascade leading to 
TM cell contraction [2].
The relative contributions of TGF-β/RhoA-induced TM 
cell contractility to the pathogenesis of OAG remains unclear 
[32], as does the potential of RhoA/ROCK inhibitors to affect 
the underlying disease process [33]. In the present study, we 
aimed to define the relative contributions of responsive TM 
contractility and fibrosis to the raised IOP and associated 
RGC death that occur in OAG, by measuring changes in a 
rat model that raises IOP through biweekly IC injections of 
TGF-β1 and evaluating the impact on IOP of local siRNA-
mediated RhoA (siRhoA) knockdown.
METHODS
TGF-β1 was purchased from Peprotech (Cat #100–21, London, 
UK). Nuclease stable siRhoA and enhanced green fluorescent 
protein–specified siRNA (siEGFP) were manufactured and 
provided as a generous gift by Quark Pharmaceuticals Inc. 
(Ness Ziona, Israel), and Quark Pharmaceuticals has all 
proprietary rights. All other reagents were purchased from 
Sigma (Poole, UK) unless otherwise specified.
Experimental design: All animal procedures were performed 
in accordance with guidelines described in the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision 
Research, the ARRIVE guidelines and UK Home Office 
Animals Scientific Procedures Act 1986 and approved by 
the University of Birmingham Animal Welfare and Ethical 
Review Board. Thirty-five Sprague Dawley rats weighing 
180–200 g (Charles River, Kent, UK) were housed at 21 °C 
and 55% humidity under a 12 h:12 h light-dark cycle, given 
food and water ad libitum, and supervised by qualified staff. 
Anaesthesia was induced with 5% isoflurane 1.5 l/min with 
O2 (National Veterinary Supplies, Stoke, UK) and maintained 
at 3.5%. The design of each experimental component of the 
study is summarized in Table 1. The two time points of 7 days 
and 35 days were chosen based on previous studies demon-
strating considerable RGC death after 30 days, as well as the 
observation that TGF-β injections could be stopped and pres-
sure would remain high [34], suggesting that fibrosis has been 
established. The 7 day time point was chosen to represent an 
earlier time point to observe the early phase changes. At this 
time point, if TGF-β injections stops, the pressure returns to 
normal, suggesting the presence of a transient mechanism 
unlikely to be fibrosis.
Demonstration of RhoA knockdown by siRhoA: Rat retinas 
were used to demonstrate the potency of siRhoA knockdown 
in the eye, because TM tissues are small and difficult to 
isolate precisely. Therefore, increasing doses of siRhoA (10, 
15, 20, 30, and 40 ng) based on previous work with other 
siRNAs of this type [35], dissolved in a final volume of 5 
µl of PBS (1X; Potassium Phosphate monobasic-KH2PO4; 1 
Molecular Vision 2018; 24:712-726 <http://www.molvis.org/molvis/v24/712> © 2018 Molecular Vision 
714
mM, Sodium Chloride-NaCl; 155 mM, Sodium Phosphate 
dibasic-Na2HPO4-7H2O; 3 mM, pH 7.4), were injected intra-
vitreally using glass micropipettes. Animals were allowed to 
survive for 7 days before euthanasia by exposure to rising 
CO2 concentrations. The retinas were harvested, immedi-
ately frozen in RNAlater (Invitrogen, Paisley, UK) in liquid 
nitrogen, and stored at −80 ºC. Total RNA was extracted 
using TRIzol and purified according to the manufacturer’s 
instructions (Qiagen, Manchester, UK), and quantitative 
reverse transcription (RT)–PCR was performed. Briefly, 
40 ng of the reverse transcribed cDNA template was mixed 
with Universal MasterMix and either the human 18S rRNA 
endogenous control probe or the relevant TaqMan Gene 
Expression Assay and amplified on an ABI PRIZM 7700 (all 
from Applied Biosystems, Foster City, CA) set at 95 ºC for 10 
min, followed by 40 cycles of 95 ºC for 15 s and then 60 ºC 
for 1 min. PCR data were analyzed using the 2-ΔΔCt method. 
TaqMan gene expression assays were used to measure relative 
mRNA levels of genes, including rhoa, oas1, mx1, casp7, and 
ifit.
Ocular effects of siRhoA treatment in a rat glaucoma model: 
Eyes were injected IC twice a week. The eyes of eight rats 
were injected with 3.5 µl of activated TGF-β1 (5 ng/µl; n=4 
eyes) and 3.5 µl of PBS (n=4 eyes). Four rats were euthanized 
at 7 days and four at 35 days. The eyes of an additional 12 
rats were injected IC twice a week with a total volume of 7 
µl consisting of either 3.5 µl of activated TGF-β1 and 3.5 µl 
of siEGFP (5 ng/µl; n=12) or 3.5 µl of activated TGF-β1 and 
3.5 µl of siRhoA (5 ng/µl; n=12). Six of these 12 rats were 
euthanized at 7 days (referred to as the early phase), and six 
were euthanized at 35 days (referred to as the chronic phase). 
In addition, for the immunohistochemical (IHC) analysis, 
three intact eyes from three untreated rats were used as intact 
controls. The study was designed to confirm the effects of 
TGF-β1 on (i) IOP elevation and TM ECM production (previ-
ously reported elsewhere [34]) and contractile protein expres-
sion within the TM by comparing TGF-β-injected eyes with 
PBS-injected eyes and intact eyes and to assess the relative 
contribution of RhoA-mediated TM contraction during the 
early and chronic stages of TGF-β-induced IOP elevation.
IOP measurements: Immediately after induction of anes-
thesia, IOP was recorded using an iCare Tonolab rebound 
tonometer (iCare, Helsinki, Finland) as described previously 
[34]. Mean IOP values were derived from three consecutive 
sets of six recordings taken between 21:00 and 24:00 (to 
minimize circadian variability) from each eye immediately 
before each IC injection. Accurate tonometry readings are 
dependent on a healthy cornea, and in the present study, no 
thickening or calcifications were observed throughout the 
study. IOP readings are displayed as mean ± standard error 
of the mean (SEM).
Surgical procedures: At day 0, after the first IOP reading, 
the heads of anaesthetized rats were fixed in a stereotactic 
frame. The cornea was incised with a disposable 15 degree 
blade to create a self-sealing two-step incision as previously 
described [34]. The first and all subsequent IC injections 
were administered through the incision using a sterile glass 
micropipette, produced in-house from a glass capillary rod 
(Harvard Apparatus, Kent, UK).
Table 1. experimenTal design.
Number of rats Treatment group (n=number of eyes/group) Measured endpoints
12 rats
IV Vehicle (n=4) 
5 ul IV siEGFP (20ng; n=4) 
5 ul IV siRhoA (10ng; n=4) 
5 ul IV siEGFP (15ng; n=4) 
5 ul IV siRhoA (20ng; n=4) 
5 ul IV siRhoA (30ng; n=4) 
5 ul IV siRhoA (40ng; n=4)
RT–PCR (to assess knockdown efficiency and the 
activation of innate immunity)
3 Rats Intact control eyes (n=3) IHC (contractility & fibrosis)
4 Rats
3.5 ul IC of 5ng/µl TGFβ1 (n=4) 7d IHC (contractility & fibrosis)
3.5 ul IC 3.5ul PBS (n=4) 7d IHC (contractility & fibrosis)
4 Rats
3.5 ul IC 5ng/µl TGFβ1 (n=4) 35d IHC (contractility & fibrosis)
3.5 ul IC PBS (n=4) 35d IOP; IHC (contractility & fibrosis)
6 Rats
3.5 ul IC 5ng/µl TGFβ1+5ng/µl siRhoA (n=6) 7d IOP; IHC (contractility & fibrosis)
IC 5 ng/µl TGFβ1+5ng/µl siEGFP (n=6) 7d IOP; IHC (contractility & fibrosis)
6 Rats
IC 5 ng/µl TGFβ1+5ng/µl siRhoA (n=6) 35d IOP; IHC (contractility & fibrosis)
IC 5 ng/µl TGFβ1+5ng/µl siEGFP (n=6) 35d IOP; IHC (contractility & fibrosis)
Molecular Vision 2018; 24:712-726 <http://www.molvis.org/molvis/v24/712> © 2018 Molecular Vision 
715
Immunohistochemistry: Dissected eyes were prepared for 
immunohistochemistry (using antibodies listed in Table 2) 
after the rats were euthanized at 7 days and 35 days by expo-
sure to rising CO2 concentrations, as described previously 
[34]. Briefly, animals were perfused intracardially with 4% 
paraformaldehyde (PFA; TAAB, Reading, UK). The eyes 
were removed and immersion fixed in 4% PFA for a further 
2 h at 4 °C, then cryoprotected by sequential immersion in 
10%, 20%, and 30% sucrose solution in PBS, and blocked up 
in optimal cutting temperature (OCT) embedding medium 
(Thermo Shandon, Runcorn, UK) in peel-away molds (Agar 
Scientific, Essex, UK). Radial eye cryosections were cut 
at 20 µm thick in a standard plane through the ON head 
on a cryostat (Bright Instruments Ltd, Huntingdon, UK), 
adhered on charged glass slides (SuperFrost Plus, Fisher 
Scientific, Pittsburgh, PA), and stored at −20 ºC. For subse-
quent analyses, sections were thawed at room temperature 
(RT), hydrated in PBS, permeabilized in 0.1% Triton X-100, 
washed in PBS, and encircled with a hydrophobic PAP pen 
(Immuedge pen; Vector Laboratories, Peterborough, UK). 
Non-specific protein binding sites were blocked by incu-
bating sections in blocking buffer (75 µl; 0.5% bovine serum 
albumin (BSA; g/ml), 0.3% Tween-20, and 15% normal goat/
donkey serum (Vector Laboratories, Peterborough, UK) in 
PBS) in a humidified chamber for 30 min at RT, drained, 
and incubated with primary antibodies (Table 2) diluted in 
antibody diluting buffer (ADB; 0.5% BSA, 0.3% Tween-20 
in PBS) overnight at 4 ºC. Sections were then washed and 
incubated with Alexa Fluor 488 or Alexa Fluor 594 conju-
gated secondary antibodies (Table 2) diluted in ADB for 1 h 
in a hydrated incubation chamber at RT. The sections were 
washed in PBS, mounted in Vectorshield mounting medium 
containing 4′,6-diamidino-2-phenylindole (DAPI; Vector 
Laboratories, Peterborough, UK), and stored at 4 ºC in the 
dark before the microscopic analysis. No immunoreactive 
(IR) staining was seen in the negative antibody controls in 
which the primary antibody was omitted (data not shown).
Microscopy and analysis: Immunostained eye sections were 
photographed at 20X magnification using a Zeiss Axioplan-2 
fluorescent microscope equipped with an Axiocam HRc 
camera and Axiovision software (all from Carl Zeiss, Ltd., 
Hertfordshire, UK). All images were equivalently contrast-
enhanced using Photoshop CS3 (Adobe Systems, Inc., San 
Jose, CA). Brn3a+ RGC were counted in 20 µm thick standard 
radial sections along a 250 µm linear region of the ganglion 
cell layer (GCL) at the same distance from either side of the 
ON head as validated previously in this glaucoma model and 
others [34,36]. As the TM has a very small tissue volume 
and is intimately related to the surrounding connective tissue, 
western blot and RT–PCR were inappropriate analyses for 
TM RhoA. RhoA expression and TM fibrosis, however, 
were quantified by measuring IR in the same standardized 
TM quadrant in all eyes using ImageJ software (National 
Institutes of Health, Bethesda, MD) to measure percentage 
changes in pixels compared to the threshold reference level of 
brightness in intact control eyes as previously described [34]. 
All image analysis was conducted by an operator masked to 
the group identifications.
Adult rat retinal cultures: As TM cells are difficult to isolate 
and culture, mixed adult rat retinal cultures were used as 
a representative ocular cell type to demonstrate that RhoA 
knockdown using siRhoA had no off-target effects, such as 
activating the innate immune response. Cultures were estab-
lished from the dissected retinas of Sprague Dawley rats (180–
200 g; Charles River). Briefly, retinal cells were dissociated 
into single cell suspensions using as Papain Dissociation kit, 
according to the manufacturer’s instructions (Worthington 
Biochemicals, Lakewood, NJ). Then 125,000 retinal cells 
Table 2. anTibodies used for immunohisTochemisTry.
Antigen Dilution Supplier Catalogue no.
Laminin 1:200 Sigma (Poole, UK) #L9393
Fibronectin 1:200 Sigma (Poole, UK) #F3648
αSmooth Muscle Actin (αSMA) 1:100 Sigma (Poole, UK) #A5228
Phosphorylated Myosin Light Chain 
(MLCp) 1:400 Abcam (Cambridge, UK) #ab2480
RhoA 1:200 Abcam (Cambridge, UK) #ab54835
Brn3a 1:100 Santa Cruz (Santa Cruz, CA) #SC-31984
Mouse IgG (Fluor 488) 1:400 Molecular Probes (Paisley, UK) #A-21202
Rabbit IgG (Fluor 488) 1:400 Molecular Probes (Paisley, UK) #A-21206
Rabbit IgG (Fluor 594) 1:400 Molecular Probes (Paisley, UK) #A-21207
Goat IgG (Fluor 594) 1:400 Molecular Probes (Paisley, UK) #A-11058
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were plated in eight-well chamber slides (Beckton Dickinson, 
Watford, UK) precoated with 100 µg/ml poly-D-lysine and 20 
µg/ml laminin, in supplemented Neurobasal-A (Invitrogen). 
Cells were allowed to settle overnight and then transfected 
in a final volume of 300 μl of supplemented Neurobasal-A 
with increasing concentrations (10–100 μg/ml) of siRhoA or 
a T7-transcribed sip75NTR, an siRNA that shows statisti-
cally significant upregulation of the innate immune response 
[37] using Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s protocol. Cells were transfected for 5 h and 
then topped up with fresh Neurobasal-A and incubated at 37 
ºC and 5% CO2 for a further 3 days before extraction of total 
RNA for quantitative RT-PCR (qRT-PCR) analysis.
Statistical analysis: Statistical tests were performed using 
SPSS 21.0 (IBMM SPSS, Inc., Chicago, IL), and data were 
presented as mean±SEM. The Shapiro-Wilk test was used to 
ensure all data were normally distributed before a one-way 
ANOVA (ANOVA) was applied with a Tukey post-hoc test 
for IHC analysis. For the IOP data, generalized estimated 
equations were used to determine the statistical significance 
to accommodate for the measurement dates not always being 
the same between groups. A p value of less than 0.05 was 
considered statistically significant.
RESULTS
siRhoA induces knockdown of RhoA expression in ocular 
tissues without inducing an immune response: Due to the 
very small volume of TM, we first analyzed the knock-
down of RhoA expression by siRhoA in whole eyes after 
intravitreal injection of siRNA. Increasing concentrations 
of siRhoA significantly knocked down endogenous RhoA 
mRNA extracted from retinas, with a maximum reduction 
observed with an effective dose of 15 ng of siRNA, where 
RhoA mRNA levels were reduced by 64% (Figure 1A). 
Knockdown efficiency did not increase further using siRhoA 
concentrations above 15 ng. This study guided our selection 
of 17.5 ng per injection for the in vivo TGF-β experiments.
In the mixed adult rat retinal cultures, the siRhoA at any 
of the concentrations tested between 50 and 100 μg/ml did not 
upregulate the expression of MX1 (Appendix 1 panel A), IFIT 
(Appendix 1 panel B), OAS1 (Appendix 1 panel C), or Casp7 
(Appendix 1 Panel D), which are all markers of the innate 
immune response. However, a control T7 transcribed siRNA 
to p75NTR, which we have shown previously to upregu-
late the innate immune markers above [37] significantly 
increased MX1 (Appendix 1 panel A), IFIT (Appendix 1 
panel B), OAS1 (Appendix 1 panel C), and Casp7 (Appendix 
1 panel D) by ten- to 18-fold compared to the control and 
siRhoA-treated cultures. Taken together, these results show 
that siRhoA significantly knocks down RhoA expression in 
ocular tissues in vivo and in retinal cell cultures but does not 
induce an innate immune response at doses tested well above 
those used in the in vivo studies.
Intracameral siRhoA induces knockdown of RhoA protein in 
the TM: Pixel counts of the immunoreactivity (IR) of RhoA 
expression in the TM are shown (Figure 1B) demonstrating 
a relatively low abundance of RhoA protein in the control 
PBS-injected eyes (14±3.0% IR pixel count; Figure 1C) 
and statistically significant upregulation after IC TGF-β1 
injection (51±7.0% IR pixel count; Figure 1D). Successful 
knockdown of RhoA IR was apparent in the TM at 7 days 
(6±3% IR pixel count; Figure 1E) and 35 days (5±4% IR 
pixel count; Figure 1F) after IC injections of TGF-β1+siRhoA 
when compared to TGF-β1+siEGFP (55±11% IR pixel count; 
Figure 1G). Although it cannot be assumed that the successful 
mRNA knockdown in the retina (Figure 1A) will translate 
into successful knockdown in the TM, combined with the 
reduced IR/pixel counts in the TM, siRhoA delivered IC over 
35 days suppressed the expression of RhoA protein in the 
TM for the duration of the experiment. IC siRhoA treatment 
did not affect RhoA expression in the retinal GCL (data not 
shown).
IC TGF-β1 injections induce an early and sustained rise 
in IOP, of which the first phase is RhoA dependent: In the 
TGF-β1+siEGFP-injected eyes, there was an early rise in the 
IOP between 3 and 7 days followed by a second sustained 
rise in the IOP appearing by 13 days and progressively incre-
menting up to 35 days (Figure 2). In the TGF-β+siRhoA-
injected eyes, RhoA knockdown abolished the early rise in 
IOP between 3 and 7 days (p<0.05). The later raised IOP 
measurements between 13 and 35 days were unaffected by 
RhoA knockdown, which persisted throughout this time 
interval and was significantly different from that of the 
PBS-injected eyes which remained consistently low. RhoA 
signaling in the TM, therefore, mediates the initial IOP 
response to intracameral TGF-β injection but not the later 
sustained IOP elevation.
IC TGF-β1 injection increases fibrosis of the TM at 35 days 
but not at 7 days: The percentage above-threshold pixel counts 
in the TM of IR laminin and fibronectin were similar at 7 days 
in all groups indicating that TGF-β1-induced fibrosis was not 
established by this time point, despite the early phase IOP 
elevation onset by 3 days (Figure 3). However, at 35 days in 
the TGF-β1-, TGF-β1+siRhoA- and TGF-β1+siEGFP-injected 
eyes, IR laminin and fibronectin immunofluorescence was 
raised statistically significantly by 40% above those recorded 
in the PBS-injected and intact eyes and above that seen at the 
Molecular Vision 2018; 24:712-726 <http://www.molvis.org/molvis/v24/712> © 2018 Molecular Vision 
717
7 day time point in any treatment group (Figure 3), with no 
detectable difference between the siRhoA and siEGFP eyes.
IC TGF-β1 injection induces an increase in TM contractility 
proteins in the TM at 7 days but not at 35 days: TGF-β1 injec-
tions increased IR α-SMA and MLC-p levels in the TM when 
compared to the levels in the PBS-injected and intact eyes 
at the 7 day time point but not at the 35 day time point. The 
injection of siRhoA abrogated the TGF-β-mediated increase 
in IR α-SMA and MLC-p at 7 days but not at 35 days, an 
observation that is consistent with increased TM contractility 
being an early response leading to acutely raised IOP. Accord-
ingly, at 7 days, the IR α-SMA and MLC-p pixel counts 
were statistically significantly higher in the TM after the 
TGF-β1+siEGFP treatment compared to the TGF-β1+siRhoA-
injected eyes (53±5.0% and 55±5.0% versus 35±5.0% and 
27±5.0%, respectively; Figure 4). IC TGF-β1 induced 
significantly greater IR α-SMA and MLC-p levels in the TM 
compared to IC PBS alone (42% and 61%, respectively) at 7 
days. At 35 days, the IR α-SMA and MLC-p pixel counts in 
the TM were statistically significantly lower when compared 
to 7 days in all TGF-β1+siRNA treatment groups and to the 
levels in the PBS-injected and intact eyes. Accordingly, at 
35 days, the IR α-SMA and MLC-p pixel counts in the TM 
were 28±5.0% and 17±5.0% after TGF-β1+siRhoA treatment 
Figure 1. RT–PCR and immu-
nohistochemistry demonstrate 
RhoA knockdown. A: Reverse 
transcription polymerase chain 
react ion (RT-PCR) shows a 
statistically significant (*p<0.05; 
***p<0.0001) reduction in endog-
enous RhoA mRNA in eyes treated 
with increasing concentrations of 
siRhoA. The percentage immu-
noreactivity (IR) pixel counts of 
RhoA expression in the trabecular 
meshwork (TM) for the groups 
are defined in C–G. B: Note the 
statistically significant (*p<0.0001 
difference from PBS/siRhoA) 
upregulation of RhoA protein in 
the TGF-β1-treated eyes and down-
regulation after knockdown with 
siRhoA. Radial rat eye sections 
immunohistochemically stained 
for RhoA (green) nuclear coun-
terstaining with 4′,6-diamidino-
2-phenylindole (DAPI) (blue) after 
intracameral (IC) injection with 
PBS for 35 days (C), TGF-β1 for 
35 days (D), TGF-β1+siRhoA for 
7 days (E) and 35 days (F), and 
TGF-β1+siEGFP for 35 days (G). 
Images were taken of the iridocor-
neal angle (C–G; *TM;†Schlemm’s 
canal). Note the successful knock-
down of RhoA in the TM of the IC 
siRhoA-treated eyes (E and F). All 
images are representative of the 
eight images taken per treatment 
group (scale bar=50 µm).
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compared to 34±5.0% and 26±5.0% after TGF-β+siEGFP 
injections, respectively, values that were not statistically 
significantly different from each other. In addition, at 35 days, 
eyes receiving TGF-β1 alone demonstrated low IR α-SMA 
and MLC-p pixel counts in the TM (15±4.0% and 15±3.0%, 
respectively), as did the PBS-injected eyes (16±3.0% and 
12±4.0%, respectively).
RhoA knockdown does not prevent the RGC death caused 
by TGF-β-induced raised IOP: At 7 days, the RGC counts 
were not statistically significantly different among the Intact 
control, TGF-β1, TGF-β1+siRhoA, TGF-β1+siEGFP, and 
PBS treatments (65±3.0, 54±4.0, 68.3±0.20, 67.2±0.30, and 
61.6±3.30 RGC/mm of the retina, respectively; Figure 5). 
At 35 days, there was equivalent and statistically significant 
RGC death (p<0.01) after the IC TGF-β1, TGF-β1+siEGFP, 
and TGF-β1+siRhoA injections when compared to all groups 
at 7 days, and to the 35 day PBS group and the Intact control 
group (38±2.3 after TGF-β1, 45.2±0.90 after TGF-β1+siRhoA, 
and 44.4±0.80 at 35 days after TGF-β1+siEGFP IC injec-
tions). There was no statistically significant difference in the 
RGC counts at 35 days between the TGF-β1+siRhoA- and 
TGF-β1+siEGFP-treated groups or between groups treated 
with TGF-β1 alone, suggesting that in this model RGC loss 
was initiated by the later and more sustained second phase 
of raised IOP.
DISCUSSION
Knockdown of RhoA was initially confirmed in retinal 
tissues as extraction specifically of TM tissue is surgically 
difficult and available in limited amounts. For example, in the 
retina, 15–40 ng of siRhoA delivered intravitreally was suffi-
cient to significantly reduce RhoA mRNA, a result that was 
similar to other siRNAs of this nature [35]. As it cannot be 
assumed that successful knockdown in the retina will trans-
late to knockdown in the TM, effective RhoA knockdown 
was also confirmed with IHC after IC injections of siRhoA, 
illustrated by low levels of RhoA IR in the TM after siRhoA 
treatment, confirming that IHC can be used to qualitatively 
determine the knockdown of target genes [35,38].
In siRNA-based knockdown technologies, many studies 
have reported off-target effects and in particular, activation 
of the innate immune response by the siRNA itself or the 
delivery methods [39-42]. The siRNA structure, sequence, 
and delivery methods all contribute to activation of the innate 
immune response, leading to undesired effects and misinter-
pretation of results [43]. For example, interferon stimulated 
genes, such as OAS1 (Gene ID 192281, OMIM 164350), 
MX1 (Gene ID 24575, OMIM 147150), IFIT (Gene ID 56824, 
OMIM 147690), and Casp7 (Gene ID 64026, OMIM 601761), 
are typically upregulated in response to siRNA [44-47]. 
However, the siRhoA used in this study has been modified 
by proprietary methods (Quark Phamaceutical Inc., Israel) 
and has been made stable to resist nuclease degradation such 
that activation of interferon response genes is minimal or 
Figure 2. IOP (mmHg) measure-
ments in rat eyes receiving biweekly 
IC injections of TGF-β1+siRhoA, 
TGF-β1+siEGFP, and PBS. Note 
the statistically significant acute 
intraocular pressure (IOP) rise 
between 3 days and 7 days in the 
TGF-β1+siEGFP-injected group 
compared to the TGF-β1+siRhoA- 
and PBS-injected groups (*p<0.05) 
and the lack of a statistically 
significant difference between 
the TGF-β1+siRhoA- and the 
TGF-β1+siEGFP-injected eyes in 
the chronic phase (13 days to 35 
days). The TGF-β1+siRhoA- and 
TGF-β1+siEGFP-injected eyes were 
statistically significantly different from control PBS-injected eyes in the chronic phase (13 days to 35 days;** p<0.05). TGF-β1+siEGFP 
intraocular pressure (IOP) values were not statistically significantly different from those in rats receiving TGF-β1 alone (IOP for TGF-β1 
alone was previously reported [34]).
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nonexistent. Therefore, the apparent effects of the siRhoA are 
effects mediated by target-specific knockdown of RhoA and 
not related to off-target effects, as has been observed for other 
similarly modified siRNAs [35,48].
An early and sustained rise in IOP was induced in IC 
TGF-β1-injected eyes (with or without siEGFP) characterized 
by an early rise in IOP over 4–7 days and then a gradual 
later rise in IOP over 8–35 days. The angle resembled that 
of OAG suggesting that the IOP increases induced were due 
to cellular effects of TGF-β and not to angle closure (IHC 
morphology data not shown). No early (1–7 days) spike in IOP 
was observed in the TGF-β1+siRhoA-treated eyes, but the 
later rises in IOP still developed over 8–35 days, confirming 
that RhoA mediates the early but not late TGF-β-induced rise 
in IOP. This suggests that the early phase IOP response to 
IC TGF-β1 is not associated with immunohistochemically 
detectable TM fibrosis, and the TM fibrosis seen by 35 days 
after IC TGF-β1 injections and associated with sustained IOP 
elevation is not mediated through RhoA-dependent signaling 
pathways. There was increased IR for the contractile 
proteins α-SMA and MLC-p in the TM of the TGF-β1- and 
TGF-β1+siEGFP-treated eyes during the early rise in IOP, 
which was suppressed by siRhoA. The TM IR for markers of 
fibrosis (laminin and fibronectin) at 35 days was associated 
Figure 3. Percentage of IR 
f ibronectin and laminin pixel 
counts in the TM of radial eye 
sections. Images were taken of 
defined areas centered on the 
trabecular meshwork (TM) from 
radial sections of eyes that were 
immunohistochemically stained 
for fibronectin or laminin (red). 
Samples were assessed af ter 
intracameral (IC) injection with 
TGF-β1+siRhoA for 7 days (A and 
E), TGF-β1+siEGFP for 7 days (B 
and F), TGF-β1+siRhoA for 35 days 
(C and G), TGF-β1+siEGFP for 35 
days (D and H), TGF-β1 for 7 days 
(I and N), PBS for 7 days (J and O), 
TGF-β1 for 35 days (K and P), and 
PBS for 35 days (L and Q), as well 
as untreated Intact eyes (M and R). 
All images are representative of 
eight images taken per retina from 
each treatment group (scale bar=50 
µm). All sections were nuclear 
counterstained with 4′,6-diamidino-
2-phenylindole (DAPI) (blue). The 
percentage immunoreactivity (IR) 
pixel counts in the TM are presented 
for fibronectin (S) and laminin (T) 
from the groups defined in A–R. 
Asterisks indicate the statistically 
significant differences at p<0.01 
between the same treatments at 7 
days and the 35 days, whereas the 
black lines indicate statistically 
significant differences at p<0.05 
between groups at 35 days.
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with the chronic rise in IOP in the TGF-β1-, TGF-β1+siEGFP-, 
and TGF-β1+siRhoA-treated eyes when contractile protein IR 
was decreased. Similar numbers of RGCs died at 35 days 
in the TGF-β1+siRhoA- and TGF-β1+siEGFP-treated eyes, 
correlated with the consistent induction of the late rise in IOP 
by TGF-β1 despite the siRNA treatment.
An early and sustained rise in IOP and chronically 
increased production of ECM by human Tenon’s fibro-
blasts [14] has been experimentally induced by TGF-β1 and 
TGF-β2, although in pathology the predominant role of the 
former may be in inflammation [10], and of the latter in 
fibrogenesis as shown in other studies from scar tissue in the 
lesioned spinal cord [14,49]. Aberrant rises in IOP associated 
with perturbed AqH drainage and TM fibrosis occur in rat 
eyes after adenoviral transfection of TM cells with TGF-β2 
[50,51] and after biweekly IC injection of TGF-β1 and TGF-β2 
[34]. Adenoviral gene transfection of TGF-β2 in secreted 
protein acidic and rich in cysteine (SPARC) knockout mice 
demonstrated a SPARC-dependent IOP rise and upregula-
tion of collagen IV and fibronectin levels after 8 days [50]. 
However, the key fibrogenic proteins, laminin, and collagen 
I/VI were not upregulated at this time point, suggesting that 
the major fibrotic responses do not develop until after 8 days. 
Figure 4. Percentage of IR α-SMA 
and MLCp pixel counts in the TM 
of radial eye sections. Images are 
of defined areas centered on the 
trabecular meshwork (TM) taken 
from sections of radially sectioned 
eyes that were immunohistochemi-
cally stained for alpha smooth 
muscle action (α-SMA) and myosin 
light chain (MLC) p (MLCp; 
green). Samples were assessed from 
rats intracameral (IC) injected with 
TGF-β1+siRhoA for 7 days (A and 
E), TGF-β1+siEGFP for 7 days (B 
and F), TGF-β1+siRhoA for 35 
days (C and G), TGF-β1+siEGFP 
for 35 days (D and H), TGF-β1 for 
7 days (I and N), PBS for 7 days (J 
and O), TGF-β1 for 35 days (K and 
P), and PBS for 35 days (L and Q), 
as well as untreated Intact eyes (M 
and R). All images are representa-
tive of the eight images taken per 
retina from each treatment group 
(scale bar=50 µm). All sections 
were nuclear counterstained with 
4′,6-diamidino-2-phenylindole 
(DAPI) (blue). The percentage 
immunoreactivity (IR) pixel counts 
in the TM are presented for α-SMA 
(S) and MLCp (T) from the groups 
defined in A–R. Asterisks indicate 
the statistically significant differ-
ences at p<0.05 between the same 
treatments at 7 days and 35 days, 
whereas the black lines indicate 
statistically significant differences 
(p<0.05) between groups at 7 days.
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However, the TM fibrotic responses of mice and rats may 
differ as exemplified in the spinal cord of mice which express 
significantly more laminin than do rats at 8 days post-lesion 
[52].
The findings reported here are consistent with the obser-
vation that TGF-β induces an early phase of rapid activation 
of RhoA signaling in TM cells so that the actin cytoskeleton 
is mobilized to cause cellular changes associated with TM 
contraction and thus, alter the stiffness of TM permitting 
resistance. This is followed by a later phase in which RhoA 
becomes downregulated [53], suggesting that the acutely 
raised IOP, characteristic of early glaucomatous disease, 
may be RhoA-mediated and amenable to RhoA-targeted 
treatment. Furthermore, we have shown here and previously 
[34] that the later phase of IOP elevation seen after IC TGF-β1 
is caused by TM fibrosis, but it seems that the initiation of 
TM fibrosis is multifactorial and therefore, is not solely 
reliant on RhoA signaling, as the initiation is not modulated 
by siRhoA knockdown highlighting a need for a multifacto-
rial approach to treatment. It may be beneficial to target the 
Figure 5. Brn3a+ RGC counts in 
radial eye sections. Standardized 
areas of the ganglion cell layer are 
shown in sections immunohisto-
chemically stained for Brn3a (red) 
prepared from rats intracamerally 
(IC) injected with TGF-β1+siRhoA 
for 7 days (A), TGF-β1+siEGFP for 
7 days (B), TGF-β1+siRhoA for 35 
days (C), TGF-β1+siEGFP for 35 
days (D), TGF-β1 for 7 days (E), 
PBS for 7 days (F), TGF-β1 for 35 
days (G), and PBS for 35 days (H), 
as well as untreated Intact eyes (I). 
All images are representative of 
the eight images taken per retina 
from six different animals (scale 
bar=50 µm). All images are nuclear 
counterstained with 4′,6-diamidino-
2-phenylindole (DAPI) (blue). In 
(J), the mean number of Brn3a+ 
RGC/mm of retina is presented with 
counts from the control PBS-treated 
eyes shown by a dashed line. Aster-
isks indicate the significantly lower 
(p<0.01) RGC counts in the 35 day 
groups compared to the counts 
made from their respective 7 day 
groups as well as the PBS-treated 
and Intact control groups. 
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contraction and stiffness of the TM and Schlemm’s canal with 
antifibrotic agents [54,55]. The results of the present in vivo 
study demonstrate that siRhoA treatment can suppress the 
early but not the later rise in IOP induced by elevated TGF-β 
levels. That is, in this model TGF-β initiates rapid rises in IOP 
through RhoA-induced cellular changes that are associated 
with TM contractility and maintains TM resistance by later 
initiating fibrosis. Cultures of human TM cells expressing a 
constitutively active form of RhoA express not only increased 
contractility markers (raised α-SMA and MLC-p levels) but 
also express fibrotic proteins (laminin and fibronectin) [56]. 
Expression of a constituently active form of RhoA in the AqH 
drainage pathway led to overexpression of not only contrac-
tility markers but also the fibrosis marker collagen. RhoA 
kinase inhibitors ameliorated the rise in collagen expression. 
However, IOP increased by only approximately 2 mmHg in 
their study suggesting that RhoA overexpression resulted in 
a small amount of fibrosis relative to other models [57]. We 
have demonstrated in rat eyes in vivo decreased fibronectin 
IR intensity at 35 days in the TGF-β1+siRhoA-treated eyes 
compared to the TGF-β1+siEGFP-treated eyes, suggesting a 
modest resolution of fibrosis from siRhoA treatment in this 
group only. Taken together with the laminin levels, however, 
which did not reduce with siRhoA treatment, we suggest that 
the TGF-β1-mediated fibrosis shown in this model is unre-
sponsive to RhoA inhibition, suggesting other mechanisms 
lead to fibrosis or that, once fibrosis is established, RhoA 
inhibition alone is not sufficient to normalize TM function. 
Perhaps a combinatorial approach of RhoA inhibitors with 
antiscarring agents [34] would be beneficial to patients where 
fibrosis is present.
Rapid rises in IOP are induced by RhoA-mediated TM 
contraction in enucleated porcine eyes [31,56]. Others have 
shown upregulation of collagen mRNA over the first 3 days 
after IC TGF-β1 injection, when an early rise in IOP was also 
observed, with no associated increase in TM fibrotic protein 
levels, although mRNA changes are not always associated 
with protein changes and typically precede them [15,58-
60]. Moreover, the transient fall in IOP observed between 8 
days and 13 days described in this study, despite continuous 
TGF-β1 administration, suggests that TM fibrosis is not 
responsible for the acute phase rise in IOP.
Although undetected at 7 days, RGC death at 35 days 
was about 45% in all eyes associated with TGF-β1-induced 
chronically raised IOP, consistent with our previous work 
[34] and including those in which the early rise in IOP was 
abolished by siRhoA (TGF-β1+siRhoA- treated eyes). These 
results suggest that the progression of RGC death up to 35 
days is causally related to the development of chronically 
raised IOP; i.e., that sustained raised IOP resulting from 
TM fibrosis is the major causal factor for RGC death in this 
model. RhoA is constitutively expressed in RGC somata and 
axons [61] and elevated in the optic nerve head in patients 
with glaucoma [62]. Although retinal RhoA knockdown by 
intravitreal siRhoA injections is RGC neuroprotective after 
optic nerve crush in rats [63], this effect was not seen in the 
TGF-β1-treated eyes that also received IC siRhoA, presum-
ably because neuroprotective doses were not delivered to the 
GCL due to restricted anterior to posterior chamber transfer 
and remained within the TM as shown in a previous gene 
expression study [64]. This observation is consistent with 
preserved retinal RhoA IR despite immunohistochemically 
detectable knockdown in TM cells in the anterior segment 
after IC siRhoA injections. Our assessment of RGC survival 
used cell counting on sagittal eye sections, which we have 
previously demonstrated is an accurate method in this and 
other models of retinal injury [34,36]. However, the sensi-
tivity of this method of assessing RGC survival means that 
it is unlikely to detect subtle differences in RGC numbers 
when compared to counts made in retinal whole mounts, 
and we cannot exclude a modest effect on RGC survival of 
intracameral siRhoA treatment in this model.
RhoA-mediated transient TM contractility is implicated 
in the genesis of diurnal variable and progressive day and 
night IOPs, reported to cause pathological glaucomatous 
changes [65-69]. Nocturnal spikes in IOP, in association with 
lowered nocturnal blood pressure, can cause retinal hypoper-
fusion episodes, optic nerve and retinal ischemia-reperfusion 
injury, and RGC loss. Of relevance, expression of dominant-
negative RhoA in the TM lowers nocturnal IOP spikes in an 
animal model of glaucoma [70].
The efficacy of RhoA inhibitors currently used in clin-
ical practice for lowering chronically elevated IOP in patients 
with glaucoma [71-73] suggests that a reversible element of 
TM contraction remains responsible for a proportion of IOP 
elevation even in established disease, in contradiction to 
our rodent model of stable fibrosis-induced IOP elevation, 
which lacks a reversible element amenable to treatment by 
RhoA knockdown. This indicates that there are aspects of 
the TM disease process not captured by its characterization 
as a TGF-β1-driven TM fibrosis etiology. Thus, more refined 
models of POAG pathogenesis may be required to fully 
assess the clinical impact of RhoA inhibitors. In addition, rats 
have different responses to IOP-lowering medications than 
humans, with prostaglandin analogs transiently elevating 
IOP [74], suggesting that outflow pathways and their control 
mechanisms may differ between species.
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In summary, IC TGF-β induced an early and late rise in 
IOP by elevating TM resistance and reducing AqH drainage. 
The early rise in IOP over the 4–7 day period was caused 
by a RhoA-dependent mechanism with concurrent cellular 
changes associated with TM cell contraction, while the later 
rise in IOP was attributed to RhoA-independent TM fibrosis. 
RGC death was causally related to the late but not the early 
rise in IOP.
APPENDIX 1. SUPPLEMENTARY FIGURE 1.
Reverse transcription PCR shows the expression of the innate 
immune response markers MX1 (A), IFIT (B), OAS1 (C), and 
Casp7 (D) in mixed adult rat retinal cultures after siRhoA 
treatment (0.5-100 μg/ml) in comparison to a positive control 
T7 transcribed siRNA to p75NTR. Statistical significance 
(p<0.001) is present at all concentrations of siRNA tested. 
To access the data, click or select the words “Appendix 1.”
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